Home > Boards > US OTC > Medical - Healthcare >

GT Biopharma Inc. (GTBP)

Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board: 
Last Post: 3/16/2018 10:29:54 AM - Followers: 169 - Board type: Free - Posts Today: 0


Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!


Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.



Company Website


Corporate Overview - Presentation
Fall 2015
Click the link:





OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet




Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.


Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.


Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.


Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.


Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.


Stock Information:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Initial Statement of Beneficial Ownership (3) 03/16/2018 05:15:54 PM
GTBP News: Securities Registration Statement (simplified Form) (s-3/a) 03/15/2018 04:18:01 PM
GTBP News: Securities Registration Statement (simplified Form) (s-3/a) 03/15/2018 04:13:33 PM
GTBP News: Amended Current Report Filing (8-k/a) 03/15/2018 04:08:19 PM
GTBP News: Annual Report (10-k) 03/01/2018 04:23:50 PM
News News Alert: Initial Statement of Beneficial Ownership (3) 03/16/2018 05:15:54 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#11468   Nice uptick this morning with decent bids stacking up Oharper 03/16/18 10:29:54 AM
#11467   Hey Josh, 4 posts in 4 years....... What are mrcraigo 03/15/18 11:29:05 AM
#11466   this is bad news ya? joshanderson 03/14/18 02:14:02 PM
#11465   Nobody has anything to say about the filing? simon wagstaff 03/02/18 11:09:18 AM
#11464   Oharper 02/28/18 03:48:32 PM
#11463   ~ Thanks "Cash" - you have told me LAQUEST 02/28/18 10:11:50 AM
#11462   I can't offer anymore than the filings. OXIS CashBowski 02/28/18 09:47:01 AM
#11461   They say; "The third time is the charm!" LAQUEST 02/24/18 02:01:45 PM
#11460   Hi "Cash," I am new here and was LAQUEST 02/22/18 02:35:00 PM
#11459   Hi "billymack" - I'm new here, LAQUEST 02/21/18 12:10:38 PM
#11458   Maybe if they do a third reverse split scoot27 02/20/18 01:43:15 PM
#11457   Why does this stock suck so bad? bmel 02/15/18 04:17:44 PM
#11456   Under a buck next week? simon wagstaff 02/15/18 04:15:58 PM
#11455   Under two bucks. Let's see the close. simon wagstaff 02/15/18 12:56:20 PM
#11454   I guess we'll see what happens billymack 02/15/18 11:48:05 AM
#11453   How so? Their chances of uplisting right simon wagstaff 02/15/18 11:35:57 AM
#11452   Definitely a vote of confidence for GTBP I billymack 02/15/18 10:30:38 AM
#11451   Looks like under 2 bucks by tomorrow, maybe today. simon wagstaff 02/15/18 10:08:19 AM
#11450   NEWS Oharper 02/15/18 09:09:38 AM
#11449,_ simon wagstaff 02/09/18 10:55:08 AM
#11448   Nice push off the open! Oharper 02/08/18 09:37:04 AM
#11447   Another green open for us. GTBP rebound billymack 02/08/18 09:34:08 AM
#11446   Already surpassed yesterday's volume too Oharper 02/07/18 02:46:54 PM
#11445   Nice rebound so far from the $2 mark. billymack 02/07/18 02:16:29 PM
#11444   Under two bucks, maybe today. simon wagstaff 02/07/18 09:41:06 AM
#11443   Well that's enticing. Looks like you've now billymack 02/06/18 01:10:23 PM
#11442   Under a buck in two weeks. simon wagstaff 02/06/18 12:58:36 PM
#11441   Still waiting for a true support to hold here. billymack 02/06/18 12:33:06 PM
#11440   Everything was down yesterday lol. read the billymack 02/06/18 12:30:45 PM
#11439   LOL, simon wagstaff 02/06/18 10:38:42 AM
#11438   Yeh nice bid sizes coming in Oharper 02/06/18 10:22:29 AM
#11437   Steam? down 48 cents yesterday, up a simon wagstaff 02/06/18 10:11:48 AM
#11436   Looks like GTBP is catching some steam this billymack 02/06/18 09:33:57 AM
#11435   I thought about it too, still holding long Oharper 02/02/18 03:53:38 PM
#11434   Bought the dip today billymack 02/02/18 03:50:02 PM
#11433   Volume looking good still too Oharper 01/31/18 03:01:55 PM
#11432   That's what I'm seeing as well. billymack 01/31/18 02:52:37 PM
#11431   Looks like it's holding support at its low Oharper 01/31/18 02:51:02 PM
#11430   GTBP Chart billymack 01/31/18 02:38:37 PM
#11429   What’s that mean? jasonstocktrader 01/31/18 02:32:10 PM
#11428   I'm unsure of the logistics of it too.. Thanks! Oharper 01/30/18 11:48:43 AM
#11427   Sure, please see my previous post that outlines simon wagstaff 01/30/18 11:34:53 AM
#11426   That's what I was asking, but if they Oharper 01/30/18 11:08:41 AM
#11425   They don't qualify for uplisting. simon wagstaff 01/30/18 09:19:36 AM
#11424   Not yet, was hoping you knew more than Oharper 01/29/18 03:26:16 PM
#11423   Not yet, was hoping you knew more than Oharper 01/29/18 03:26:15 PM
#11422   All I know is that they applied. Other billymack 01/29/18 03:16:18 PM
#11421   Thanks, you know anything about the uplisting? Oharper 01/29/18 03:15:12 PM
#11420   Here: billymack 01/29/18 03:12:56 PM
#11419   I don't think so, mind sharing the link? Oharper 01/29/18 03:11:26 PM